A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

Part of paid clinical trials in Glendale, California.

Sponsor
Jade Biosciences, Inc.
Study ID
NCT07525947
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers (HV)

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • JADE101 — DRUG
    JADE101 is supplied as sterile solution to be administered by SC injection

Study Details

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.

Key Dates

Start date
May 1, 2026
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: JADE101 Groups 1 and 2
    Subcutaneous (SC) injection of JADE101
  • Experimental: JADE101 Groups 3 and 4
    Subcutaneous (SC) injection of JADE101

Primary Outcome Measure

Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participants [ Time Frame: Day 1 through 48 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Parexel Early Phase Clinical Unit (EPCU)GlendaleCalifornia91206
Han
[email protected]
+1-888-228-7425

Find similar trials in Glendale, CA

By research site
Parexel Early Phase Clinical Unit (EPCU)· Glendale, CA

Related Studies